Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture
Learn about Efficacy in Plaque Psoriasis PSO | CIMZIA® (certolizumab pegol)
Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment
New Novartis data shows Cosentyx™ is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients | Novartis
SIMPONI ARIA® Psoriatic Arthritis Efficacy: PASI Response | HCP
View Image
Major Secondary Endpoints: Moderate to Severe Plaque Psoriasis | TREMFYA® (guselkumab) HCP
Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients - Khatri - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Figure 2 | Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis | SpringerLink
Solved Health State transition PASI 75 maintain PASI 75 PASI | Chegg.com
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study - Lebwohl - 2020 - Journal of the European Academy
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
Absolute Versus Relative Psoriasis Area and Severity Index in Clinical Practice | Actas Dermo-Sifiliográficas
STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan | PLOS ONE
What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis - Practical Dermatology
Novartis Dubai Figure 01 - Key Opinions in Medicine
Plaque Psoriasis (PsO) Clinical Trials | Enbrel® (etanercept)
PASI score: Definition and how to calculate
PASI-75 Response with Otezla in the Treatment of Moderate to Severe Plaque Psoriasis — Efficacy | Otezla® (apremilast) Healthcare Professional Site
NNTs show once-unimaginable psoriasis outcomes now readily attainable | MDedge Rheumatology
JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study | HTML
STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
Open-label Extension Data: Moderate to Severe Plaque Psoriasis | TREMFYA® (guselkumab) HCP
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period ...
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial - ScienceDirect
